30 results about "Plasma insulin" patented technology

The present invention relates to novel mangiferin calcium and its preparation and use. The mangiferin calcium can lower plasma insulin, glucose, lipid, also can improve the solubility and oral bioavailability of mangiferin.

The present invention provides a method for achieving a therapeutically effective plasma levels of insulin by admmisteppg at least two doses of pharmaceutical formulation of insulin sequentially into the same nostril The administration of the second dose in the same nostril gives substantially higher plasma levels of insulin when compared with sequential administration in two different nostpls Without being limited to any specific physiological mechanism, it is believed that the first dose of insulin acts as a loading dose This loading dose is required to achieve the subsequent plasma levels of insulin that are observed with subsequent doses The Cmax of plasma insulin achieved by the methods and formulations of the present invention is at least about 7Q microU / ml when plasma insulin is measured from about 0 to about 45 minutes after administration of a second dose The AUC achieved is at least about 1800 microU / (ml* mm).

An insulin infusion device includes a processor architecture, and a memory element that stores executable instructions to perform a method of controlling delivery of insulin to a user. The method operates the device in a closed-loop mode to deliver insulin, obtains patient-specific parameters for a current time sample, and estimates a plasma insulin value and a blood glucose value for the user based on at least some of the patient-specific parameters. The estimating is also based on a previously estimated plasma insulin value obtained for a previous time sample, and a previously estimated blood glucose value obtained for the previous time sample. A predicted sensor glucose value is generated for the current time sample, and the closed-loop mode or a safe basal mode is selected for controlling operation of the insulin infusion device in accordance with the selected mode.

Methods and modules for using physiological (biometric) variables to advance the state of the artificial pancreas. The method and system includes one or more modules for recursive model identification, hypoglycemia early alert and alarm, adaptive control, hyperglycemia early alert and alarm, plasma insulin concentration estimation, assessment of physical activity (e.g., presence, type, duration, expected effects on insulin sensitivity and GC), detection of acute stress and assessment of its impact on insulin sensitivity, detection of sleep and its stages and assessment of sleep stages on GC, sensor fault detection and diagnosis, software and controller performance evaluation and adjustment and / or pump fault detection and diagnosis.

A method and a system for determining insulin sensitivity (IS) is described. In one aspect the method and the system can be implemented by receiving a first parameter corresponding to an insulin dose in a subcutaneous tissue; applying a first kinetic model to obtain a plasma insulin concentration based on the first parameter; receiving a second parameter corresponding to a plasma glucose concentration; determining the insulin sensitivity (IS) based on the plasma insulin concentration and the second parameter.

The invention provides application of pinitol to pharmacy and health care product. Compared with the prior art, the invention has the beneficial effects that: novel medical application and health care application of a known compound is explored, and a new application field is developed; the product has rich source and simple preparation process, can be prepared into an oral preparation, an injection and tablet, and is convenient for use; the configured drug product or health care product has effects of increasing plasma levels of pinitol and D-chiro-inositol, and decreasing plasma insulin and glucose levels; and the configured drug product or health care product has effects of reducing the blood sugar value, insulin level, plasma lipid and plasma triglyceride.

A method for controlling an insulin injection pump, a related control unit (200), and an injection pump (300). The control unit (200) comprises: an expected plasma insulin concentration value acquiring module (202), a current subcutaneous and interstitial insulin concentration value acquiring module (201), a supposed injection value acquiring module (203), an injection instruction sending module (204), and a counting module (205). The injection pump comprises a pump body and the control unit (200), and the control unit (200) is disposed in the pump body.

The present invention relates to novel mangiferin calcium and its preparation and use. The mangiferin calcium can lower plasma insulin, glucose, lipid, also can improve the solubility and oral bioavailability of mangiferin.

The present invention refers to the use of an antisense DNA oligonucleotide for the messenger RNA of the PGC-la protein, useful as drug for the treatment of diabetes mellitus, insulin resistance and metabolic syndrome. More specifically, the present invention deals with a compound used as drug, through enteral or parenteral route, preferably, with the property of inhibiting the protein expression peroxisome proliferator-activated receptor alpha Coactivator 1 (PGC-la) leading to the reduction of the blood glucose levels. It deals, therefore, with a pharmacological compound that promotes, in diabetic and insulin-resistant individuals, improvement of the glucose serum levels, increase of the plasmatic insulin concentration and reduction of insulin resistance. The present invention presents a more effective control of the glucose levels and acts beneficially on other complications associated to the Diabetes and obesity conditions, according to tests performed in animal models. In this manner, the principal advantage of the present invention over others alike already existing in the market is the effectiveness that controls blood glucose levels and the fact of acting beneficially on other complications that accompany the disease.